CBT’s silk road
Why OrbiMed Asia-backed CBT is looking to China for innovative oncology assets
While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop in the West and elsewhere.
“Tremendous private and public capital infusion in China has led to promising innovative products developed by Chinese companies,” President and CEO Sanjeev Redkar told BioCentury. But he said many of those companies are not equipped to develop their